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Trachoma is one of the most widespread blinding eye diseases, which is harmful to human visual health. The efforts to prevent 
and control trachoma in China can be divided into three periods, i.e., highly epidemic period, research on pathogenesis and 
control of trachoma, and blinding trachoma elimination and epidemiological evaluation. In 1956, Prof. Feifan Tang and Xiao-
lou Zhang first discovered and isolated Chlamydia trachomatis, which clarified the cause of trachoma, and kick-started a fresh 
chapter in trachoma research, prevention, and control around the world. Although, the prevalence of trachoma differed in dif-
ferent areas, the average prevalence once exceeded 50% and was as high as 90% in some areas before and at early liberation of 
China. Therefore, the government-led efforts were made to comprehensively prevent and control trachoma, including devel-
opment of National Plan for the Prevention and Control of Trachoma, nationwide screening and treatment of trachoma, im-
plementation of National Patriotic Health Campaign and improvement of water supply and lavatories. After decades of effort, 
China reached the goal of eliminating blinding trachoma in 2015. China has gained remarkable achievements in the prevention 
and treatment of trachoma, making outstanding contributions toward the goal of eliminating trachoma worldwide. The research, 
prevention, and control of trachoma in China were reviewed in this paper. 
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Trachoma, which is one kind of chronic infectious conjunc-
tivitis, is caused by Chlamydia trachomatis infection. Pa-
tients have obvious symptoms, including eye pain, photo-
phobia, tears, itching, and irritation, even vision loss. In 
addition to the clinical signs of palpebral conjunctiva, e.g., 
follicular and papillary hyperplasia, most patients usually 
suffer from conjunctival scarring, corneal pannus, and Her-
bert’s pits typical performance. Repeated infection may 
cause enstrophe, trichiasis, ptosis, atretoblepharia, and even 
blindness by macular cornea at the end stage. The preven-
tion and control of trachoma in China can be characterized 
by three periods as follows: highly epidemic period, com-
prehensive trachoma prevention and control period, and 
blinding trachoma elimination and evaluation period. The 
objective of this paper is to review studies concerning the 
prevention and control of trachoma in China. 
HIGHLY EPIDEMIC PERIOD 
Before liberation, trachoma was widespread in China owing 
to economic issues and poor sanitation. The average preva-
lence of trachoma was about 50%, with the prevalence rate 
of 30% in urban areas and as high as 80%–90% in remote 
rural areas was, resulting in the proverb that “nine out of ten 
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were caught in trachoma” (Wang et al., 2015). In total, 
25%–37% of blindness was caused by trachoma (Jin, 2006; 
Wang et al., 2015; Ji, 1944). Before 1955, the pathogenic 
mechanisms were not clear, and trachoma spread as a major 
cause of blindness worldwide for a long time. It was once 
called the “dark district of ophthalmology” for the lack of 
clear etiology (Jin, 2006). The mechanism underlying the 
early prevalence of trachoma was mainly unknown; thus, no 
targeted prevention or control measures could be taken. To 
identify certain microorganism as trachoma pathogen, 
Koch’s postulates should be followed, which include the 
following requirements: (i) the organism must be isolated 
from the corresponding cases; (ii) to the microbe must be 
subcultured in vitro, separately; (iii) vaccination of the iso-
lated microorganisms must produce lesions and symptoms 
in healthy hosts; (iv) the microbe must be isolated again 
from the vaccinated host. 
Internationally, there were several theories about tra-
choma pathogens, including Koch’s trachoma germ theory 
and Noguchi’s trachoma particles Escherichia coli pathogen 
theory. However, most studies have failed to retain strains 
or to be confirmed by repeated experiments performed by 
other groups. Accordingly, they fail to meet the four princi-
ples of Koch’s criteria; thus, it was not possible to deter-
mine the cause of trachoma. In the spring of 1929, Prof. 
Feifan Tang, a member of the first generation of Chinese 
microbiologists and virologists, started to work on identify-
ing the trachoma pathogen. Using the conjunctival biopsies 
of 227 patients as sources, Prof. Feifan Tang and ophthal-
mologist Prof. Chenghu Zhou still failed to isolate bacillus 
particles by bacterial culture after hundreds of attempts 
from 1932 to 1935. Moreover, no infection appeared when 
the Noguchi bacillus strain particles were inoculated to the 
eyes of monkeys or 12 volunteers, including those of Feifan 
Tang. In an additional agglutination experiment and com-
plement fixation experiment, there were no differences with 
respect to the use of particles as antigens in the results for 
patients with and without trachoma, thus rejecting Nogu-
chi’s theory (Tang and Zhou, 1936). 
After the establishment of People’s Republic of China, 
deadly infectious diseases were highly controlled; thus, the 
focus of epidemic prevention efforts shifted to multiple 
standard infectious diseases. In 1954, Prof. Feifan Tang, the 
director of Nation Vaccine & Serum Institute began to study 
trachoma pathogens in cooperation with Prof. Xiaolou 
Zhang, an ophthalmologist from Beijing Tongren Hospital.  
Prof. Feifan Tang and Xiaolou Zhang’s trachoma patho-
gen research included three main stages: trachoma inclusion 
studies, the inoculation of trachoma-positive inclusion ma-
terial to monkeys, and pathogen separation experiments 
(Tang et al., 1956a, b, c, 1957a, b, 1958; Li et al., 1956, 
1964; Zhang and Zhang, 1965; Chang et al., 1960). Based 
on an analysis of the successes and failures of predecessors 
in separating the “trachoma virus”, Prof. Feifan Tang found 
that pathogen separation was mainly influenced by two fac-
tors: (i) the sensitivity of animals and appropriate route of 
infection and (ii) the control of bacterial breeding in speci-
mens. After hundreds of thousands of experiments, they 
ultimately chose to vaccinate chicken embryonic yolk sacs 
with a “trachoma virus”, and adjusted the specimens added 
to 1,000 units of streptomycin; these were maintained at 
4°C for 4 h. In August of 1955, for the first time, they suc-
cessfully isolated trachoma pathogenic agents: “Chlamydia 
TE55 standard strains” (Tang et al., 1956c, 1957a). In order 
to confirm the trachoma virus cultivated in the chicken em-
bryo yolk sac as a trachoma pathogen, Feifan Tang and 
Xiaolou Zhang inoculated themselves in January of 1956. 
Based on daily observations and conjunctival smears, they 
finally found trachoma inclusions in the typical clinical 
signs and conjunctiva smears, and cultivated the “trachoma 
virus” separately several times.  
The fact that the “trachoma virus” was separately culti-
vated in the chicken embryo strongly indicated that it was a 
trachoma pathogen (Zhang and Zhang, 1965; Li et al., 1964). 
In 1970, “trachoma virus” was formally renamed “Chlamydia 
trachomatis” during the international symposium on tracho-
ma and related diseases caused by Chlamydia.  
With over 50 years of intensive efforts, Chinese scientists 
finally isolated trachoma pathogens, which represented a 
major international advance in the fields of microbiology 
and ophthalmology. In 1957, medical delegations from the 
US and UK asked Prof. Feifan Tang for the separated 
strains TE8 and TE55 during their visit to China. Dr. Colli-
er, director of the British trachoma team, vaccinated chicken 
embryos after recovery and cultivated Chlamydia with his 
teammates, validating the experimental results of Feifan 
Tang and others. In 1958, by following Feifan Tang’s 
method, Collier and Sowa managed to isolate 1 strain in the 
western African country of Gambia, which was named tra-
choma strain G1. They also obtained positive results when 
the strain was inoculated to the eyes of monkeys and volun-
teers. In 1959 and later, Saudi Arabia, the United States, 
Israel, Egypt, Japan, and other countries successively iso-
lated many strains of “trachoma virus”. In 1960 and 1961, 
Lepine, chairman of the International Conference on Tra-
choma, highly praised China’s effort in isolating Chlamydia 
and named the TE55 strain “Tang’s strain”, which could be 
used worldwide as the standard strain for trachoma re-
search. Due to this unique contribution, Prof. Feifan Tang 
was awarded Trachoma Gold Medal by International Or-
ganization Against Trachoma. 
RESEARCH ON PATHOGENESIS AND 
CONTROL OF TRACHOMA 
The discovery of Chlamydia laid a foundation for the pre-
vention and treatment of trachoma and Chlamydia, starting 
a new chapter in the study of the prevention and treatment 
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of Chlamydia trachomatis. China carried out studies on 
typing, toxins, serological properties, pathogenic mecha-
nism, local immunity, the transmission mode, treatment, 
development of vaccines and preventive measures from the 
perspective of clinical service and public health, and pro-
moted SAFE (Surgery for Trichiasis, S; Antibiotic Treat-
ment, A; Face Washing, F; and Environmental Improve-
ments, E) strategy nationwide to comprehensively prevent 
and control trachoma.  
Pathogenesis of trachoma  
In 1956, Feifan Tang measured the Chlamydia trachomatis 
size as 0.13–0.2 µm (Tang et al., 1956c), while Xiaolou 
Zhang reported a size of 0.311–0.477 µm using an electron 
microscope (Zhang and Zhang, 1965). In 1973, Tao Hong 
studied the microstructure of Chlamydia trachomatis, and 
observed equal and unequal divisions (Hong et al., 1973). In 
1956, using volunteer and monkey eye infection tests, Fei-
fan Tang and Xiaolou Zhang confirmed that human and 
monkey eyes were sensitive to Chlamydia trachomatis, 
while rabbits, guinea pigs, dogs, sheep, and other animals 
were not susceptible (Tang et al., 1956b, c, 1957a). Typical 
trachoma inclusions were found when Feifan Tang and oth-
ers injected Chlamydia trachomatis into chicken embryo 
yolk sac endodermal cells, human embryonic kidney cells, 
human embryo conjunctiva, and HeLa cells. Zihua Li and 
others isolated Chlamydia trachomatis from chicken em-
bryo yolk sac endoderm and HeLa cells and maintained it 
passaging for five generations. These studies laid the foun-
dation for cell cultures of trachoma (Tang et al., 1958; Li et 
al., 1963, 1964). In 1956, based on observations of tracho-
ma inclusions, such as morphological classifications and 
effects on cell properties, Feifan Tang and others advanced 
the idea that the inclusions were trachoma and the initial 
colony form, or the reticulate body, was the source of infec-
tion of trachoma pathogens, and found it replicate after the 
initial infection (Tang et al., 1956a). Xiaolou Zhang and 
others found that the reproductive cycle of Chlamydia tra-
chomatis is 48–72 h in duration (Zhang et al., 1965). In 
1980, Youxun Zhang and others studied the ultrastructure of 
Chlamydia trachomatis and found that the splitting original 
body and large individual actually breed by binary fission, 
budding, multicenter germinal methods, and so on, clarify-
ing the life cycle of trachoma (Zhang et al., 1980). Keqian 
Wang, Xiaolou Zhang, and others confirmed that Chlamyd-
ia trachomatis can produce toxins, which were antigenic 
and sensitive to temperature. Penicillin treatment could 
make Chlamydia trachomatis lose its chlamydial infection 
ability and maintain toxin activity, while immune serum 
could neutralize these toxins. These findings laid the basis 
for further studies on trachoma immunity (Wang and 
Zhang, 1966). 
Xiaolou Zhang, among others, began serological studies 
of Chlamydia trachomatis in China since 1960 (Zhang and 
Zhang, 1965). In 1964, Keqian Wang found a significant 
antigen consistency among trachoma strains (Zhang et al., 
1980; Wang and Huang, 1964). In 1966, Keqian Wang 
found that 46 strains of trachoma “virus” obtained from 
separation experiments in Beijing, Shanghai, Henan, and 
other places could be divided into two types, types I and II 
(Wang and Zhang, 1966). In 1991, Zhang Li and other re-
searchers classified Chlamydia trachomatis discovered in 
northern China. They found that 78.1% and 21.9% sequence 
similarity between the isolates from northern China and 
type B and type C reference strains, verifying the idea of 
KeQian Wang that the type I Chlamydia trachomatis TF55 
was type C (Zhang and Zhang, 1991). In 1992, Jun Fan and 
Wenhua Zhang used two kinds of synthetic primers to per-
form PCR amplification as a detection method for tracho-
matous specimens. This method enabled the rapid detection 
of eye infection by Chlamydia trachomatis, and indicated 
that the positive rate increased to 70.6% (Fan et al., 1992). 
In 2007, PCR-based gene classification was performed by 
Yumei Zhou and others, revealing that the major type in 
China was type B (Zhou et al., 2007), and the major geno-
type of patient in the clinical ophthalmology was still type 
B, representing 56%, while type C represented 25% and 
type D represented 19%. Types B and C showed high ho-
mology with the gene pool and trachoma of the same type 
spread in the endemic area of China, while type D showed 
certain differences (Zhou et al., 2013). 
Based on the analysis of conjunctival cytology, follicular 
pathology, and Chlamydia Xiuying Jin, Xiaolou Zhang, and 
others further clarified the pathogenesis of trachoma (Jin et 
al., 1980; Wang et al., 1980), pointing out that recovery 
from the initial infection was possible, while repeated infec-
tion might cause a delayed hypersensitivity reaction. Addi-
tionally, an increasing number of repeated infections would 
cause more severe pathological injury, leading to higher 
morbidity and sequelae and ultimately inducing blindness. 
Hence, devoted efforts to treat acute trachoma, cut off 
transmission routes, and prevent super-infection were of 
great significance (Jin et al., 1980). 
Drug studies 
In 1956–1962, Feifan Tang, Xiaolou Zhang, Zhenxi Ma, 
and others discovered that while geomycin, terramycin, 
penicillin, chloromycetin, and sodium hyaluronate could 
inhibit trachoma, streptomycin could not. More than 100 
various Chinese herbal medicines tested by Zhen Xi Ma and 
others limited the process of virus breeding (Tang et al., 
1956c; Lu and Xu, 1955; Ma et al., 1962; Zhang and Jin, 
1962a). The Ophthalmology Department at the No. 3 Hos-
pital of Beijing University used an herbal pill named 
Huatiedan to treat trachoma and obtained a cure rate of 
48.6% within two weeks in 1959 (Department of Ophthal-
mology, 1959). In 1972, Xiaolou Zhang and other research-
ers checked 220 herbal medicines and 19 local Chinese 
herbal eye drops, and found that these drugs could inhibit 
Chlamydia trachomatis using in vitro tests, but none were 
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effective in vivo (Zhang et al., 1974). In 1962, Xiaolou 
Zhang and others prepared 0.1% rifampicin eye drops to 
treat trachomas. The cure rate reached 47.5% in four weeks 
and 88.1% in six weeks, suggesting the application of ri-
fampicin eye drops for the treatment of trachoma in Chinese 
ophthalmology three years earlier than this strategy was 
adopted in foreign countries (Zhang, 1977). 
Research on preventive measures 
Results of studies on localized premunition of trachoma and 
vaccine use carried out by Xiaolou Zhang and Xiuying Jin 
in 1963–1964 indicated that a localized premunition existed 
in the internal ocular surface for a period within the 
post-healing time of trachoma. Though it failed to reduce 
high-dose virus, self-vaccine-injection could provide im-
munity to a certain degree, increasing resistance to natural 
infection and protecting the lateral eye from infection 
(Zhang et al., 1963; Chang et al., 1964). To adopt effective 
prevention methods and gain predictive control in patho-
phoresis, Xiaolou Zhang and Xiuying Jin carried out a se-
ries of studies in 1966, and found that heat sterilization was 
the most convenient and effective way to prevent trachoma 
transmission in homes and public areas. Due to its strongest 
inactivation ability against Chlamydia trachomatis, 75% 
ethanol was an effective disinfectant; it can be used by 
healthcare workers to disinfect their hands and dental in-
struments (Chang and Chin, 1962; Zhang and Jin, 1962b). 
Promotion of SAFE strategy 
Increased attention was paid to trachoma prevention by the 
new Chinese government. Specifically, the prevention and 
treatment of trachoma was included in the national devel-
opment programe in 1956 and National Plan for the Preven-
tion and Control of Trachoma; nationwide screening and 
treatment of trachoma as well as a campaign named “na-
tional prevention and treatment of trachoma through im-
provement of water supply and lavatories” were carried out 
in 1957–1959. As early as 1958, China put forward the 
strategy of combining the prevention and treatment of tra-
choma with National Patriotic Health Campaign and advo-
cated preventive measures, such as one towel for each per-
son, face washing with running water, refraining from eye 
rubbing with hands, use of clean water and comprehensive 
prevention and control of trachoma, which coincide with the 
SAFE strategy put forth by World Health Organization.  
Meanwhile, the prevention and treatment of trachoma in 
China was tailored to its national conditions, as the Chinese 
government continuously increases investment in rural 
medical force development and rural medical insurance 
system to perfect the three-tiered medical network, relies on 
medical and health facilities at all levels, give full play to 
urban-rural medical network, emphasizes the publicity and 
education on health aimed at improving the health aware-
ness of the general public in the prevention and treatment 
efforts. In the first nationwide survey in 1987, trachoma fell 
to the third leading cause of blindness, rather the leading 
cause, explaining approximately 10.87% of all causes of 
blindness (Zhang et al., 1992). 
In May 1990, the World Health Organization (WHO) 
Collaborating Centre for the Prevention of Blindness in 
China (Beijing Institute of Ophthalmology, Beijing Tongren 
Hospital) held a training course on the simplified WHO 
trachoma grading system—for the first time in China. Prof. 
Baochen Sun invited WHO advisor Dr. Konyama to be the 
lead lecturer. In November 1991, Prof. Sun and Dr. Kon-
yama carried out a survey of trachoma in Kunming, and 
continuously promoted simplified WHO trachoma grading 
system of the WHO.  
In 1999, the team led by Prof. Baochen Sun obtained the 
written permission and funding from the WHO headquarters 
in Geneva and translated the four handbooks on trachoma 
control into Chinese. These books were published in Janu-
ary 2000 and were distributed to provinces, municipalities 
and autonomous regions in China. Since then, Prof. 
Baochen Sun and Prof. Ailian Hu organized training cours-
es and promote the simplified WHO trachoma grading sys-
tem and SAFE strategy by lecturing, showing videos or 
demonstrating. They made an outstanding contribution to 
trachoma prevention and control and the elimination of 
blinding trachoma in China.  
In September 1999, the Chinese government signed the 
“VISION 2020” declaration initiated by WHO and the 
Non-governmental organizations (NGOs), and solemnly 
swore to eliminate avoidable blindness by 2020, indicating 
the start of a new period in the prevention and treatment of 
trachoma in China. 
BLINDING TRACHOMA ELIMINATION AND 
EPIDEMIOLOGICAL EVALUATION 
In November 1999, the WHO cooperated with National 
Health and Family Planning Commission of the People’s 
Republic of China (NHFPC), performed by the National 
Institute of Hospital Administration, to hold a workshop on 
the assessment and management of trachoma in Kunming of 
Yunnan province, pointing out that about 6 million trichia-
sis patients might require surgery in China, which is of pri-
ority in the fight against trachoma in our country. 
In 2003, on behalf of China, Prof. Ningli Wang attended 
the Seventh Meeting of the WHO Alliance for the Global 
Elimination of Blinding Trachoma, a meeting held at the 
WHO headquarters in Geneva. According to epidemiologi-
cal data in China, the WHO assessed the prevalence of tra-
choma, pointing out that China was still a country with a 
large population of trachoma patients, with 26 million ac-
tive trachoma patients (TF+TI) and three million trichiasis 
patients (TT) (Table 1 shows the simplified WHO trachoma 
grading system). 
Currently, in the face of its reality, China’s primary task 
in achieving the goals of “VISION 2020” and eliminating 
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blinding trachoma in China was to evaluate the nationwide 
prevalence of trachoma. 
To investigate the nationwide epidemiological status of 
trachoma and discuss China’s strategy for prevention, Prof. 
Ningli Wang, and his team invited international officials 
specialized in blindness prevention, including Dr. Konya-
ma, Dr. Mariotti, Dr. Resnikoff, Dr. Para and Pro. Taylor, to 
China for a short-term visit. Furthermore, they actively ad-
vocated the National Health and Family Planning Commis-
sion of the People’s Republic of China (NHFPC, the former 
Ministry of Health), the China Disabled Persons’ Federation 
(CDPF), international NGOs and Mr. Ronggen Tan, who 
was working in the Lions Clubs International, to work to-
gether.  
In 2004, their efforts brought a program called “Elimi-
nating Blinding Trachoma in China”, a program financially 
and technically supported by the WHO, and they started 
preliminary experimental evaluations on the elimination of 
blinding trachoma in China. By reviewing the related liter-
ature, analyzing data, and seeking advice based on other 
useful information, they rapidly screened, treated, and 
evaluated children under the age of 10 and adults 50 years 
or older around provinces and areas with high suspected 
trachoma prevalence, such as Sichuan, Yunnan, Qinghai, 
Chongqing, Shanxi, Beijing, Guangdong, Heilongjiang, 
Inner Mongolia, Yunnan, Hainan, Hebei, Jilin, Jiangxi, Xin-
jiang, and Tibet. In the program, Prof. Ailian Hu and Prof. 
Tongtong Cui led the local medical forces specialized in 
blindness prevention to carry out the screening of trachoma 
among children, and 59,630 children were screened, and 
559 positive cases of TF were detected, with a positive rate 
of 0.94%. Among them, the positive rate in 2004 was up to 
3.89%, while the rates in 2005, 2006, and 2007 were 0.39%, 
0.33%, and 1.22%, with no TT- and CO-positive cases. The 
rates in Shanxi and Chongqing were both above 5%, and the 
trachoma TF positive detection rate for children under age 
10 in the country were all less than 1% in the other 13 prov 
inces, showing that trachoma was unevenly distributed (Hu 
et al., 2015). 
According to the trachoma screening results in the popu-
lation of individuals 50 years old and above, including a 
total of 82,434 people who were screened from 2004 to 
2007, 284 cases were positive for TT, and the positive rate 
was 0.34%. These patients all acquired trachoma infection 
in the 20th century, when the disease was highly prevalent 
in China; thus, they were named “old trachoma patients”. In 
the second nationwide survey in 2006, trachoma fell to the 
11th leading cause of blindness (Hu et al., 2015). The rate 
of blindness caused by trachoma decreased considerably, 
therefore, trachoma is no longer a leading cause for blind-
ness. 
The above results contributed to the approval for project 
“Eliminating blinding trachoma in China before 2016”. In 
September of 2012, together with the Lions Clubs Interna-
tional, NHFPC launched the third phase of “Vision First, 
China Action” project in Beijing, i.e., “Eliminating blinding 
trachoma in China before 2016”. The office for “Vision 
First, China Action” project was set in National Institute of 
Hospital Administration, with both Prof. Jialiang Zhao and 
Prof. Ningli Wang as co-chairmen of the expert panel. A 
series of studies, including screening, treatment and evalua-
tion on the effect of prevention and treatment efforts were 
carried out under the common effort by the expert panel, Dr. 
Resnikoff and Dr. Mariotti from WHO and other domestic 
ophthalmologists and blinding-prevention workers in 16 
provinces with previously high incidences, covering 8,163 
children under the age of nine in 130 schools and 
87,924,355 residents over 15 years old in 55,679 villages.  
All of the work was completed by the end of 2014, 
showing that the morbidity among 1–9 year olds was less 
than 5%, while the rate of trichiasis among adults was less 
than 1‰ (Hu et al., 2016), meeting the WHO standard of 
eliminating blinding trachoma, and fulfilling the task of 
eliminating blinding trachoma five years early, indicating 
that trachoma was no longer a public hygiene problem af-
fecting vision health. On May 18, 2015, Bin Li, Minister of 
National Health and Family Planning commission of the 
PRC, made an announcement in a general speech on the 
68th World Health Assembly that China met the WHO re-
quirement of eliminating the blinding trachoma in 2014. 
In order to determine whether there is biological variation 
between the current Chlamydia trachomatis and the previ-
ous pathogenic bacteria, and to evaluate the properties of 
the remaining sporadic trachoma, such as its pathogenicity, 
intensity, transmission routes, and so on, Prof. Ningli Wang 
and the medical team from the Beijing Institute of Oph-
thalmology made many trips to Qinghai in 2014–2015, 
conducting a broad range of trachoma prevention and 
treatment research in the medically underserved area, which 
is widely known as “the world of old, young, remote, and 
poor”. Their surveys in rural primary schools of Dunhua, 
Huangyuan, and Huzhu in Qinghai Province identified sev- 
Table 1  Simplified WHO trachoma grading system 
Grade Clinical signs 
Trachomatous inflammation follicles (TF) Five or more follicles of >0.5 mm on upper tarsal conjunctiva 
Trachomatous inflammation intense (TI) Inflammatory thickening obscuring more than half of the normal deep tarsal vessels 
Trachomatous conjunctival scarring (TS) The presence of easily visible scars in the tarsal conjunctiva 
Trachomatous trichiasis (TT) At least one eyelash rubbing on the eyeball or evidence of recent removal of in-turned eyelashes 
Cornea opacity (CO) Opacity of the cornea involving part of the pupil margin 
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eral cases of sporadic trachoma.  
In May and December of 2015, they investigated the stu- 
dents in two boarding primary schools in Galeng District, 
Salar autonomous County, Haidong City of Qinghai Prov-
ince and found 26 students with Chlamydia trachomatis 
among 322 students using RT-PCR detection. The ompA 
gene sequence of these 26 subjects had 99% similarity with 
the sequence of type B. By comparing the homology of 
ompA among 11 subjects, they also found a missense muta-
tion occurring in the 2nd conserved region, where an ade-
nine (A) was converted to a guanine (G) (ACT to GCT). As 
a result, the 91st amino acid changed from Thr to Ala. This 
missense mutation existed in all 26 subjects. Additionally, 
in the fourth variable region at the 887th site, a missense 
mutation occurred in which a thymine (T) was converted to 
a cytosine (C) (GCA to GTA), resulting in a change at the 
296th amino acid from Ala to Val (A to V); four in 26 sub-
jects presented this missense mutation. Compared with 
ATCC VR-573, six mutation sites were detected. These 
genes were divided into two groups according to the muta-
tion at site 887, named CQZ-1 (Qinghai-1) and CQZ-2 
(Qinghai-2).  
The record of prevalence of trachoma can date back to 
thousands of years. China, once holding the largest popula-
tion of trachoma patients (accounting 1/4–1/3 of the world’s 
total), now have eliminated blinding trachoma in China af-
ter the unremitting efforts of several generations of re-
searchers. China has gained remarkable achievements in the 
prevention and treatment of trachoma, making outstanding 
contributions toward the goal of eliminating trachoma 
worldwide.  
Although China has reached the goal of eliminating 
blinding trachoma, it does not mean that China no longer 
has trachoma cases. Hence, further efforts need to be made 
to promote simplified WHO trachoma grading system, tra-
choma rapid assessment, and SAFE strategies at a broader 
scale to prevent the recurrence of trachoma (Wang et al., 
2015). 
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